<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10022">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042105</url>
  </required_header>
  <id_info>
    <org_study_id>CTONG1303</org_study_id>
    <nct_id>NCT02042105</nct_id>
  </id_info>
  <brief_title>A Prospective Epidemiologic Study of ALK-Positive NSCLC in China</brief_title>
  <acronym>C-TALK</acronym>
  <official_title>A Prospective Epidemiologic and Clinical Feature Study of Non-Small Cell Lung Cancer (NSCLC) Patients With ALK Positive in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Association of Clinical Trials</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-marketing, observational, non-interventional, multi-central study of patients
      with non-small cell lung cancer (NSCLC), with data collected prospectively from medical
      records at inclusion. The primary objective is to obtain the epidemiologic data of
      anaplastic lymphoma kinase (ALK)-positive in unselected Chinese patients with NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Archived paraffin-embedded and fresh frozen NSCLC tumor tissue will be obtained via the
      Department of Pathology. ALK positive status will be detected by Ventana
      immunohistochemistry (IHC) (Ventana Medical Systems, Inc. and Roche Diagnostics
      International, Inc). When ALK positive patients are detected, crizotinib will be
      administrated by various solutions based on physician's desecration and patients'
      willingness.

      The secondary objectives include: 1.To obtain the epidemiologic data of ALK positive in
      unselected Chinese patients with NSCLC.2.To describe demographic, socioeconomic [such as
      age, gender, race/ethnicity, geographic location (including rural/urban area), pathologic
      parameters, education, family income, National Reimbursement Drug List (NRDL) or Provincial
      Reimbursement List (PRDL)], and clinical characteristics of NSCLC patients with ALK
      positive.

      The exploratory objective is to describe prognosis patterns associated with crizotinib
      treated patients when efficacy data are available non-interventionally.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>the frequency of ALK rearrangement in unselected Chinese patients with non-small cell lung cancer</measure>
    <time_frame>one and half years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>demographic, socioeconomic,clinical and pathological features of ALK-positive NSCLC patients</measure>
    <time_frame>one and half years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>prognosis patterns associated with crizotinib treated patients when efficacy data are available non-interventionally.</measure>
    <time_frame>one and half years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        unselected Chinese patients with non-small-cell lung cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (â‰¥18 years), both sex.

          -  Histologically or cytologically proven diagnosis of primary NSCLC, including squamous
             cell carcinoma and adenocarcinoma.

          -  Written informed consent.

        Exclusion Criteria:

          -  Those lung cancers without pathological diagnosis should not be included in case of
             other types of cancer, including small cell lung cancer (SCLC) or metastatic disease
             from other organs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Long Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi-Long Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Ji Yang, MD</last_name>
    <phone>+86 20 83827812</phone>
    <phone_ext>50810</phone_ext>
    <email>yangjinji2003@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhou, MD</last_name>
    <phone>+86 20 83827812</phone>
    <phone_ext>51221</phone_ext>
    <email>gzzhouqing@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Ji Yang, MD</last_name>
      <phone>+86 20 83827812</phone>
      <phone_ext>50810</phone_ext>
      <email>yangjinji2003@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qing Zhou, MD</last_name>
      <phone>+86 20 83827812</phone>
      <phone_ext>51221</phone_ext>
      <email>gzzhouqing@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jin-Ji Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Ji Yang, MD</last_name>
      <phone>86 20 83827812</phone>
      <phone_ext>50810</phone_ext>
      <email>yangjinji2003@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qing Zhou, MD</last_name>
      <phone>86 20 83827812</phone>
      <phone_ext>51221</phone_ext>
      <email>gzzhouqing@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi-Long Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 19, 2014</lastchanged_date>
  <firstreceived_date>November 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small-cell lung cancer</keyword>
  <keyword>anaplastic lymphoma kinase</keyword>
  <keyword>immunohistochemistry</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
